<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.97128</article-id><article-id pub-id-type="publisher-id">ACM-31261</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190700000_45331306.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  二甲双胍对胃癌抗肿瘤作用的研究进展
  Research Progress on Anti-Tumor Effect of Metformin in Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贺</surname><given-names>礼琴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>双双</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>义朝</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>07</month><year>2019</year></pub-date><volume>09</volume><issue>07</issue><fpage>831</fpage><lpage>836</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目前越来越多的证据表明，二甲双胍除了具有降低血糖的作用外，还可降低糖尿病患者的癌症发生风险，先前的研究表明二甲双胍可以单独作用或与某些抗癌药物协同作用，通过腺苷单磷酸活化蛋白激酶(Adenosine 5'-monophosphate (AMP)-activated protein kinase，AMPK)信号通路对各种类型的肿瘤产生抗肿瘤作用。然而，二甲双胍对胃癌的抗肿瘤作用研究较少。本文结合国内外文献，介绍了二甲双胍在胃癌抗肿瘤作用中的不同机制，从基因、信号通路到对胃癌细胞系和胃癌干细胞的功能影响以及肿瘤细胞与肿瘤微环境之间的相互作用，并综述如下。
    At present, more and more evidence that metformin has the effect of lowering blood sugar; it also can reduce the cancer risk of diabetes. Previous research has shown that metformin may work alone or in combination with some anticancer drugs synergy, through single adenosine phosphate activated protein kinase (Adenosine 5'-monophosphate (AMP)-activated protein kinase, AMPK) signaling pathway having antitumor effects on various types of cancer. However, metformin re-search on antitumor effect of gastric cancer is less in this paper. Combined with domestic and for-eign literature, this paper introduces the metformin in different mechanisms of antitumor, gastric cancer from genes, signaling pathways to the function of gastric cancer cell lines and gastric cancer stem cells and the interaction between tumor cells and tumor microenvironment. And they summarized as follows. 
   
   
    
  
 
</p></abstract><kwd-group><kwd>二甲双胍，胃癌，抗肿瘤作用, Metformin</kwd><kwd> Gastric Cancer</kwd><kwd> Anti-Tumor Effect</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>二甲双胍对胃癌抗肿瘤作用的研究进展<sup> </sup></title><p>贺礼琴，张双双，冯义朝</p><p>延安大学附属医院，陕西 延安</p><p><img src="//html.hanspub.org/file/4-1570979x1_hanspub.png" /></p><p>收稿日期：2019年6月23日；录用日期：2019年7月8日；发布日期：2019年7月15日</p><disp-formula id="hanspub.31261-formula22"><graphic xlink:href="//html.hanspub.org/file/4-1570979x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目前越来越多的证据表明，二甲双胍除了具有降低血糖的作用外，还可降低糖尿病患者的癌症发生风险，先前的研究表明二甲双胍可以单独作用或与某些抗癌药物协同作用，通过腺苷单磷酸活化蛋白激酶(Adenosine 5'-monophosphate (AMP)-activated protein kinase，AMPK)信号通路对各种类型的肿瘤产生抗肿瘤作用。然而，二甲双胍对胃癌的抗肿瘤作用研究较少。本文结合国内外文献，介绍了二甲双胍在胃癌抗肿瘤作用中的不同机制，从基因、信号通路到对胃癌细胞系和胃癌干细胞的功能影响以及肿瘤细胞与肿瘤微环境之间的相互作用，并综述如下。</p><p>关键词 :二甲双胍，胃癌，抗肿瘤作用</p><disp-formula id="hanspub.31261-formula23"><graphic xlink:href="//html.hanspub.org/file/4-1570979x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1570979x7_hanspub.png" /> <img src="//html.hanspub.org/file/4-1570979x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 介绍</title><p>胃癌(Gastric cancer, GC)是全球发病率第四位的恶性肿瘤，在肿瘤中致死率居第二位 [<xref ref-type="bibr" rid="hanspub.31261-ref1">1</xref>] ，由于其恶性程度高，是最常见的癌症类型之一。胃癌的传统治疗方法有胃切除术和放化疗，即使在根治切除和辅助放化疗后，其复发率和死亡率也很高，5年总生存率(Overall survival，OS) &lt; 25% [<xref ref-type="bibr" rid="hanspub.31261-ref2">2</xref>] ，而且70%以上的胃癌发生在发展中国家，东亚的发病率占世界总量的一半，且主要发生在中国 [<xref ref-type="bibr" rid="hanspub.31261-ref3">3</xref>] 。因此，在这种背景下开发新的有效的治疗方法是改善GC预后的必要条件。</p><p>二甲双胍是一种公认的降糖药物，也被认为是治疗2型糖尿病的一线药物 [<xref ref-type="bibr" rid="hanspub.31261-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref5">5</xref>] 。它通过抑制糖异生而降低肝脏葡萄糖的产生，改善骨骼肌对葡萄糖的摄取，降低胰岛素抵抗 [<xref ref-type="bibr" rid="hanspub.31261-ref6">6</xref>] ，与其他降糖药物相比，二甲双胍不会导致体重增加和低血糖风险增加。除了降血糖特性，流行病学研究表明，接受二甲双胍治疗的糖尿病患者比未接受二甲双胍治疗的患者患癌症的风险明显降低 [<xref ref-type="bibr" rid="hanspub.31261-ref7">7</xref>] 。Evans等 [<xref ref-type="bibr" rid="hanspub.31261-ref8">8</xref>] 首先假设二甲双胍可以降低罹患癌症的风险,他们对糖尿病患者进行了试点病例对照研究，发现二甲双胍治疗的糖尿病患者的癌症发生率为36.4%，而其他降糖药物治疗糖尿病患者的癌症发生率为39.7%。Wu等人 [<xref ref-type="bibr" rid="hanspub.31261-ref9">9</xref>] 在2015年的一项荟萃分析中评估了二甲双胍在2型糖尿病患者中的使用情况，结果显示，与未接受二甲双胍治疗的糖尿病患者相比，接受二甲双胍治疗的糖尿病患者的发病率降低了14%，死亡率降低了30%。此外，其他荟萃分析 [<xref ref-type="bibr" rid="hanspub.31261-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref13">13</xref>] 也得到了类似的结果，表明二甲双胍总体上降低了患癌症的风险。虽然一些实验室和流行病学研究表明二甲双胍可能在糖尿病患者中发挥普遍的抗肿瘤作用，但二甲双胍是否能降低胃癌等特定类型癌症的风险仍不清楚。因此，本文综述旨在阐明二甲双胍在胃癌中抗肿瘤作用的研究进展。</p></sec><sec id="s4"><title>2. 二甲双胍对胃癌细胞株具有抗增殖作用</title><p>Kato等 [<xref ref-type="bibr" rid="hanspub.31261-ref14">14</xref>] 在体内外研究了二甲双胍对不同GC细胞株(MKN1、MKN45、MKN74)的影响。他们发现，随着二甲双胍剂量的增加及时间的延长降低体外细胞增殖的效应越强，在体内他们对裸鼠皮下注射了MKN74细胞，每日腹腔注射二甲双胍1或2 mg，连续4周，在治疗结束时，治疗组小鼠的肿瘤明显小于对照组小鼠。这是因为二甲双胍在体内和体外均阻断了G(0)-G(1)的细胞周期，这种阻断伴随着G(1)细胞周期蛋白的大量减少，尤其是在cyclin D1、周期蛋白依赖性激酶(Cdk) 4、Cdk6中，以及视网膜母细胞瘤蛋白(Rb)磷酸化水平的降低。</p></sec><sec id="s5"><title>3. 二甲双胍抑制上皮细胞向间质转化</title><p>Shiva等 [<xref ref-type="bibr" rid="hanspub.31261-ref15">15</xref>] 发现二甲双胍通过对上皮–间质转化(Epithelial-mesenchymal transition，EMT)的抑制作用，对胃癌细胞的侵袭和迁移具有较强的抑制作用，其作用随着时间延长而增强，且不受培养基葡萄糖浓度的影响。单争争等 [<xref ref-type="bibr" rid="hanspub.31261-ref16">16</xref>] 发现IL-6作为肿瘤炎症微环境的重要组成部分，能通过诱导胃癌细胞发生EMT而增强其侵袭转移能力，加重病情，而经二甲双胍处理后，这种效应能得到明显的抑制。Huang等 [<xref ref-type="bibr" rid="hanspub.31261-ref17">17</xref>] 发现二甲双胍通过抑制Bmi-1来抑制EMT，Bmi-1是一种促进肿瘤细胞自我更新和上皮向间质转化的转录调控因子，其上调与肿瘤的进展有关。这种抑制作用是依赖于TNF-ɑ (LITAF)转录因子，LITAF被转移到细胞核中，在细胞核中诱导不同mi-RNA的表达：hsa-miR-15a、hsa-miR-194、hsa-miR-128、和hsa-miR-192，这些mi-RNA降低了Bmi-1的表达。Li等人 [<xref ref-type="bibr" rid="hanspub.31261-ref18">18</xref>] 的研究通过长链非编码RNA (Long nincoding RNAs，lncRNA)分析了二甲双胍处理的AGS细胞系中长链非编码RNA (lncRNA)的表达水平。已知lncRNAH19在胃癌组织中过表达。他们发现，lncRNAH19在二甲双胍存在的情况下显著下调,在二甲双胍存在条件下的lncRNAH19下调可能是AMPK活化和MMP9表达降低的原因。经二甲双胍处理后lncRNAH19在体外对细胞迁移和侵袭的依赖减少，在体内抑制肿瘤的形成，当把lncRNAH19敲除后的效果与二甲双胍治疗的效果相同，因此lncRNAH19可能是二甲双胍抑制胃癌细胞侵袭过程中的关键成分。</p></sec><sec id="s6"><title>4. 二甲双胍抑制超音hedgehog基因在胃癌细胞中的表达</title><p>已知超音hedgehog基因(Sonic hedgehog，Shh)信号通路异常激活可导致胃癌 [<xref ref-type="bibr" rid="hanspub.31261-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref21">21</xref>] ，且通路的激活对维持胃(Cancer stem cell，CSC)特性(自我更新和耐药)至关重要。Song等 [<xref ref-type="bibr" rid="hanspub.31261-ref22">22</xref>] 发现二甲双胍可以调节Shh信号通路，在胃癌细胞株中(HGC 27和MKN 45)，Shh经二甲双胍作用后降低，使用小干扰RNA (si-RNA)抑制腺苷酸激活蛋白激酶(AMPK)后，这种效应消失 [<xref ref-type="bibr" rid="hanspub.31261-ref23">23</xref>] 。因此，二甲双胍是通过AMPK来抑制Shh信号通路。</p></sec><sec id="s7"><title>5. 二甲双胍通过抑制HIF1ɑ/PKM2信号来抑制胃癌的发展</title><p>Chen等人 [<xref ref-type="bibr" rid="hanspub.31261-ref24">24</xref>] 的研究发现缺氧诱导因子1ɑ (HIF1ɑ)和丙酮酸激酶M2 (PKM2)在胃癌组织中高表达，二甲双胍通过抑制HIF1ɑ和PKM2的表达来抑制恶性行为的GC细胞，从而诱导细胞凋亡，抑制细胞入侵和胃癌细胞的迁移。</p></sec><sec id="s8"><title>6. 二甲双胍通过激活AMPK和抑制mTOR/AKT信号通路，在人AGS胃腺癌细胞中 触发固有的凋亡反应</title><p>LU等 [<xref ref-type="bibr" rid="hanspub.31261-ref25">25</xref>] 研究报道发现二甲双胍对人AGS胃腺癌细胞具有较强的抗增殖作用和诱导凋亡特性。经二甲双胍处理后增加了腺苷酸活化蛋白激酶(AMPK)的磷酸化，降低了AKT、列帕霉素(mTOR)和p70S6k的磷酸化,用化合物C(AMPK抑制剂)抑制AMPK磷酸化后，显著消除二甲双胍对AGS细胞活力的影响。二甲双胍改变凋亡相关信号通路，通过下调AGS细胞中BAD磷酸化和Bcl-2、pro-caspase-9、pro-caspase-3、pro-caspase-7表达，上调BAD、细胞色素c和Apaf-1蛋白水平完成的。吴诗文等 [<xref ref-type="bibr" rid="hanspub.31261-ref26">26</xref>] 研究发现二甲双胍呈时间-剂量依赖性抑制AGS细胞增殖，二甲双胍还可协同顺铂(DDP)、阿霉素(ADM)、紫杉醇(PTX)3种化疗药物促进AGS细胞凋亡。竹梦等 [<xref ref-type="bibr" rid="hanspub.31261-ref27">27</xref>] 发现二甲双胍和奥沙利铂联合用药时抑制SGC-7901细胞的增殖，抑制SGC-7901细胞cyclin D1的mRNA和蛋白表达水平，抑制SGC-7901细胞中抗凋亡蛋白Bcl-2 的mRNA和蛋白表达水平，增加促凋亡蛋白Bax以及凋亡执行caspase3的mRNA和蛋白表达水平，两者联合应用时比单用药物时的调控力度大。二甲双胍与奥沙利铂能够抑制胃癌细胞的增殖并诱导细胞发生凋亡，可能是通过促进Bax和caspase3的表达，抑制cyclin D1和Bcl-2 表达来实现的。</p></sec><sec id="s9"><title>7. 二甲双胍通过Akt通路调控胃癌干细胞的增殖与凋亡</title><p>查璐琴等 [<xref ref-type="bibr" rid="hanspub.31261-ref28">28</xref>] 研究报告称二甲双胍可通过抑制Akt信号通路抑制胃癌干细胞增殖并诱导其凋亡。他们发现，胰岛素样生长因子1(Insulin-like growth factors，IGFs1)可以提高胃癌干细胞中Akt和p-Akt蛋白表达，明显减弱二甲双胍对细胞中Akt和p-Akt的抑制作用，说明二甲双胍下调胃癌干细胞中p-Akt蛋白的表达是通过抑制Akt信号通路实现的。</p></sec><sec id="s10"><title>8. 二甲双胍靶向胃癌干细胞</title><p>Courtois等 [<xref ref-type="bibr" rid="hanspub.31261-ref29">29</xref>] 评估了二甲双胍对来源于患者的原发性肿瘤异种移植(Patient-derived xenograft，PDX)和胃癌细胞系(MKN45、AGS和MKN74)胃CSC增殖和致肿瘤特性的影响，对二甲双胍在传统的二维(2D)和三维(3D)培养体系(其中只有CSC能够形成肿瘤球)和小鼠异种移植模型体内的体外效果进行了评估。在三维培养系统中，二甲双胍可以减少肿瘤球的数量，显示其靶向CSC的能力，这种效应与CSC标志物(CD44和Sox2)表达下降和分化标志物(kruppel样因子4和MUC5AC)表达增加有关。最后，二甲双胍在体内治疗肿瘤异种移植(PDXs)导致肿瘤生长延迟，降低了CSCs的自我更新能力。</p></sec><sec id="s11"><title>9. 二甲双胍对胃癌体外及腹膜转移的抗肿瘤作用</title><p>SEKINO等人 [<xref ref-type="bibr" rid="hanspub.31261-ref30">30</xref>] 的研究发现二甲双胍抑制了所有GC系(MKN1、MKN45-GFP、KATO-III和SNU-1)的细胞增殖，并在体外低糖条件下提高了其敏感性，此外，二甲双胍通过抑制管理NF-kB信号来抑制腹膜转移，与AMPK信号途径无明显相关性。</p></sec><sec id="s12"><title>10. 二甲双胍对ALDH+胃癌干细胞的抑制作用及其机制</title><p>王一等 [<xref ref-type="bibr" rid="hanspub.31261-ref31">31</xref>] 研究发现乙醛脱氢酶(Aldehyde dehydrogenase，ALDH)细胞具有肿瘤干细胞特性，即自我更新能力、分化能力、致瘤能力。他们发现，不同浓度二甲双胍均可降低胃癌细胞MKN45中ALDH+细胞的比例，且随着二甲双胍浓度的升高，ALDH+细胞的比例明显下降，表明二甲双胍对CSC具有抑制作用。他们还进一步探索了二甲双胍对干性相关基因Oct4和Sox2表达的影响，最终Oct4和Sox2基因表达量下降与干细胞量下降有关。</p></sec><sec id="s13"><title>11. 二甲双胍可调节肿瘤细胞与肿瘤微环境的相互作用</title><p>Chen等 [<xref ref-type="bibr" rid="hanspub.31261-ref32">32</xref>] 研究表明二甲双胍能够调节GC细胞与其微环境之间的相互作用。他们从胃癌患者中分离出胃肿瘤相关成纤维细胞(Tumor-associated fibroblasts，TAFs)，这些TAFs经二甲双胍预处理后与GC细胞一起培养，与未处理的TAFs共培养的GC细胞相比，预处理的TAFs共培养的GC细胞增殖明显减少。他们发现二甲双胍对胃TAFs培养基中32种蛋白(14种上调，18种下调)的分泌有显著影响，其中钙调素样蛋白3(Calml3)在二甲双胍处理后在胃TAFs培养液中上调2.88倍。将重组Calml3蛋白加入GC细胞培养液中，模拟二甲双胍治疗TAFs的培养液，结果表明Calml3抑制了这些胃癌细胞的克隆性和增殖，所以二甲双胍是通过刺激FATs中Calml3的分泌来抑制胃癌细胞的增殖。</p></sec><sec id="s14"><title>12. 二甲双胍的潜在副作用</title><p>Aroda等人 [<xref ref-type="bibr" rid="hanspub.31261-ref33">33</xref>] 对糖尿病前期个体(空腹血糖升高、糖耐量下降、超重/肥胖)进行了前瞻性对照研究发现长期服用二甲双胍与维生素B12缺乏和贫血有关，维生素B12缺乏在一定程度上又会引起外周神经病变，故应考虑对接受二甲双胍治疗的患者进行维生素B12水平的常规检测。目前认为是二甲双胍对钙依赖膜作用的干扰所引起的，钙依赖膜作用负责维生素B12内因子在回肠末端的吸收 [<xref ref-type="bibr" rid="hanspub.31261-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref35">35</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.31261-ref37">37</xref>] 。尽管大量研究表明二甲双胍对胃癌等其他类型的癌症有一定的抗肿瘤作用，但同时了解二甲双胍治疗的潜在的不良后果也是至关重要的。</p></sec><sec id="s15"><title>13. 结论</title><p>二甲双胍是一种广泛用于治疗2型糖尿病的药物，耐受性良好，副作用较少。大量数据表明二甲双胍在胃癌中也有抗肿瘤作用，并调控已知与胃癌发生有关的不同基因、信号通路，同时，二甲双胍还能靶向胃CSC，抑制胃癌体外、腹膜转移及ALDH+胃癌干细胞，调节肿瘤细胞与肿瘤微环境之间的相互作用。这些特性均表明二甲双胍是一种有前途的新型的胃癌抗癌药物，可提高胃癌患者的生存率，但长期作用还需要我们有待进一步去研究。</p></sec><sec id="s16"><title>文章引用</title><p>贺礼琴,张双双,冯义朝. 二甲双胍对胃癌抗肿瘤作用的研究进展Research Progress on Anti-Tumor Effect of Metformin in Gastric Cancer[J]. 临床医学进展, 2019, 09(07): 831-836. https://doi.org/10.12677/ACM.2019.97128</p></sec><sec id="s17"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31261-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yamamoto, H., Watanabe, Y., Maehata, T., et al. (2014) An Updated Review of Gastric Cancer in the Next-Generation Sequencing Era: Insights from Bench to Bedside and Vice Versa. World Journal of Gastroenterology, 20, 3927-3937.  
&lt;br&gt;https://doi.org/10.3748/wjg.v20.i14.3927</mixed-citation></ref><ref id="hanspub.31261-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Durães, C., Almeida, G.M., Seruca, R., et al. (2014) Biomarkers for Gastric Cancer: Prognostic, Predictive or Targets of Therapy? Virchows Arch, 464, 367-378. &lt;br&gt;https://doi.org/10.1007/s00428-013-1533-y</mixed-citation></ref><ref id="hanspub.31261-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Yu, J.C., Kang, W.M., et al. (2012) Treatment Strategy for Early Gastric Cancer. Surgical Oncology, 21, 119-123. &lt;br&gt;https://doi.org/10.1016/j.suronc.2010.12.004</mixed-citation></ref><ref id="hanspub.31261-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hou, Y.C., Hu, Q., Huang, J., et al. (2017) Metformin Therapy and the Risk of Colorectal Adenoma in Patients with Type 2 Diabetes: A Meta-Analysis. Oncotarget, 8, 8843-8853. &lt;br&gt;https://doi.org/10.18632/oncotarget.13633</mixed-citation></ref><ref id="hanspub.31261-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Castilla-Guerra, L., Fernandez-Moreno, M.D., Leon-Jimenez, D., et al. (2018) Antidiabetic Drugs and Stroke Risk. Current Evidence. European Journal of Internal Medicine, 48, 1-5. &lt;br&gt;https://doi.org/10.1016/j.ejim.2017.09.019</mixed-citation></ref><ref id="hanspub.31261-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, G., Myers, R., Li, Y., et al. (2001) Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action. Journal of Clinical Investigation, 108, 1167-1174. &lt;br&gt;https://doi.org/10.1172/JCI13505</mixed-citation></ref><ref id="hanspub.31261-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Decensi, A., Puntoni, M., Goodwin, P., et al. (2010) Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis. Cancer Prevention Research, 3, 1451-1461.  
&lt;br&gt;https://doi.org/10.1158/1940-6207.CAPR-10-0157</mixed-citation></ref><ref id="hanspub.31261-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Evans, J.M.M., Donnelly, L.A., Emslie-Smith, A.M., et al. (2005) Metformin and Reduced Risk of Cancer in Diabetic Patients. BMJ, 330, 1304-1305. &lt;br&gt;https://doi.org/10.1136/bmj.38415.708634.F7</mixed-citation></ref><ref id="hanspub.31261-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wu, L., Zhu, J., Prokop, L.J., et al. (2015) Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Scientific Reports, 5, Article ID: 10147. &lt;br&gt;https://doi.org/10.1038/srep10147</mixed-citation></ref><ref id="hanspub.31261-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Thakkar, B., Aronis, K.N., Vamvini, M.T., et al. (2013) Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-Analysis Using Primary Data of Published Studies. Metabolism, 62, 922-934.  
&lt;br&gt;https://doi.org/10.1016/j.metabol.2013.01.014</mixed-citation></ref><ref id="hanspub.31261-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Franciosi, M., Lucisano, G., Lapice, E., et al. (2013) Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review. PLoS ONE, 8, e71583. &lt;br&gt;https://doi.org/10.1371/journal.pone.0071583</mixed-citation></ref><ref id="hanspub.31261-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Soranna, D., Scotti, L., Zambon, A., et al. (2012) Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. Oncologist, 17, 813-822. &lt;br&gt;https://doi.org/10.1634/theoncologist.2011-0462</mixed-citation></ref><ref id="hanspub.31261-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Noto, H., Goto, A., Tsujimoto, T., et al. (2012) Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-Analysis. PLoS ONE, 7, e33411. &lt;br&gt;https://doi.org/10.1371/journal.pone.0033411</mixed-citation></ref><ref id="hanspub.31261-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kato, K., Gong, J., Iwama, H., et al. (2012) The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation in Vitro and in Vivo. Molecular Cancer Therapeutics, 11, 549-560.  
&lt;br&gt;https://doi.org/10.1158/1535-7163.MCT-11-0594</mixed-citation></ref><ref id="hanspub.31261-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Valaee, S., Yaghoobi, M.M. and Shamsara, M. (2017) Metformin Inhibits Gastric Cancer Cells Metastatic Traits through Suppression of Epithelial-Mesenchymal Transition in a Glucose-Independent Manner. PLoS ONE, 12, e0174486. &lt;br&gt;https://doi.org/10.1371/journal.pone.0174486</mixed-citation></ref><ref id="hanspub.31261-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">单争争, 王峰, 何炜, 等. 二甲双胍对IL-6诱导的胃癌SGC7901细胞上皮间质转化的影响[J]. 郑州大学学报(医学版), 2015, 50(3): 361-367.</mixed-citation></ref><ref id="hanspub.31261-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Huang, D., He, X., Zou, J., et al. (2016) Negative Regulation of Bmi-1 by AMPK and Implication in Cancer Progression. Oncotarget, 7, 6188-6200. &lt;br&gt;https://doi.org/10.18632/oncotarget.6748</mixed-citation></ref><ref id="hanspub.31261-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Li, P., Tong, L., Song, Y., et al. (2019) Long Noncoding RNA H19 Participates in Metformin-Mediated Nhibition of Gastric Cancer Cell Invasion. Journal of Cellular Physiology, 234, 4515-4527. &lt;br&gt;https://doi.org/10.1002/jcp.27269</mixed-citation></ref><ref id="hanspub.31261-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, H., Minegishi, Y., Nomoto, Y., et al. (2005) Down-Regulation of a Morphogen (Sonic Hedgehog) Gradient in the Gastric Epithelium of Helicobacter pylori-Infected Mongolian Gerbils. The Journal of Pathology, 206, 186-197.  
&lt;br&gt;https://doi.org/10.1002/path.1763</mixed-citation></ref><ref id="hanspub.31261-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Berman, D.M., Karhadkar, S.S., Maitra, A., et al. (2003) Widespread Re-quirement for Hedgehog Ligand Stimulation in Growth of Digestive Tract Tumours. Nature, 425, 846-851. &lt;br&gt;https://doi.org/10.1038/nature01972</mixed-citation></ref><ref id="hanspub.31261-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ma, X., Chen, K., Huang, S., et al. (2005) Frequent Activation of the Hedgehog Pathway in Advanced Gastric Adenocarcinomas. Carcinogenesis, 26, 1698-1705. &lt;br&gt;https://doi.org/10.1093/carcin/bgi130</mixed-citation></ref><ref id="hanspub.31261-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Song, Z., Yue, W., Wei, B., et al. (2011) Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer. PLoS ONE, 6, e17687. &lt;br&gt;https://doi.org/10.1371/journal.pone.0017687</mixed-citation></ref><ref id="hanspub.31261-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Song, Z., Wei, B., Lu, C., et al. (2017) Metformin Suppresses the Expression of Sonic Hedgehog in Gastric Cancer Cells. Molecular Medicine Reports, 15, 1909-1915. &lt;br&gt;https://doi.org/10.3892/mmr.2017.6205</mixed-citation></ref><ref id="hanspub.31261-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Chen, G., Feng, W., Zhang, S., et al. (2015) Metformin Inhibits Gastric Cancer via the Inhibition of HIF1α/PKM2 Signaling. American Journal of Cancer Research, 5, 1423-1434.</mixed-citation></ref><ref id="hanspub.31261-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lu, C.C., Chiang, J.H., Tsai, F.J., et al. (2019) Metformin Triggers the Intrinsic Apoptotic Response in Human AGS Gastric Adenocarcinoma Cells by Activating AMPK and Suppressing mTOR/AKT Signaling. Interna-tional Journal of Oncology, 54, 1271-1281. &lt;br&gt;https://doi.org/10.3892/ijo.2019.4704</mixed-citation></ref><ref id="hanspub.31261-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">吴诗文, 张自森, 刘谦, 等. 二甲双胍联合化疗药物对人胃癌AGS细胞的作用[J]. 郑州大学学报(医学版), 2017, 52(1): 37-41.</mixed-citation></ref><ref id="hanspub.31261-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">竹梦, 王建祥, 范渊, 等. 二甲双胍联合奥沙利铂抑制胃癌细胞SGC-7901的增殖和诱导凋亡[J]. 基因组学与应用生物学, 2017, 36(11): 4398-4405.</mixed-citation></ref><ref id="hanspub.31261-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">查璐琴, 韩本高, 张超杰. 二甲双胍通过Akt通路调控胃癌干细胞的增殖与凋亡[J]. 中国组织工程研究, 2019, 23(5): 657-662.</mixed-citation></ref><ref id="hanspub.31261-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Courtois, S., Durán, R.V., Giraud, J., et al. (2017) Metformin Targets Gastric Cancer Stem Cells. European Journal of Cancer, 84, 193-201. &lt;br&gt;https://doi.org/10.1016/j.ejca.2017.07.020</mixed-citation></ref><ref id="hanspub.31261-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Sekino, N., Kano, M., Matsumoto, Y., et al. (2018) The Antitumor Effects of Metformin on Gastric Cancer in Vitro and on Peritoneal Metastasis. Anticancer Research, 38, 6263-6269. &lt;br&gt;https://doi.org/10.21873/anticanres.12982</mixed-citation></ref><ref id="hanspub.31261-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">王一, 向勇平, 刘丹丹, 等. 二甲双胍对ALDH~+胃癌干细胞的抑制作用及其机制[J]. 解放军医学杂志, 2018, 43(1): 7-11.</mixed-citation></ref><ref id="hanspub.31261-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Chen, G., Yu, C., Tang, Z., et al. (2019) Metformin Suppresses Gastric Cancer Progression through Calmodulin-Like Protein 3 Secreted from Tumor-Associated Fibroblasts. Oncology Reports, 41, 405-414.  
&lt;br&gt;https://doi.org/10.3892/or.2018.6783</mixed-citation></ref><ref id="hanspub.31261-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Aroda, V.R., Edelstein, S.L., Goldberg, R.B., et al. (2016) Long-Term Metformin and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology &amp; Metabolism, 101, 1754-1761.  
&lt;br&gt;https://doi.org/10.1210/jc.2015-3754</mixed-citation></ref><ref id="hanspub.31261-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Caspary, W.F., Zavada, I., Reimold, W., et al. (1977) Alteration of Bile Acid Metabolism and Vitamin-B12-Absorption Indiabetics on Biguanides. Diabetologia, 13, 187-193. &lt;br&gt;https://doi.org/10.1007/BF01219698</mixed-citation></ref><ref id="hanspub.31261-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Berchtold, P., Dahlqvist, A., Gustafson, A., et al. (1971) Effects of a Biguanide (Metformin) on Vitamin B 12 and Folic Acid Absorption and Intestinal Enzyme Activities. Scandinavian Journal of Gastroenterology, 6, 751-754.  
&lt;br&gt;https://doi.org/10.3109/00365527109179948</mixed-citation></ref><ref id="hanspub.31261-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Bauman, W.A., Shaw, S., Jayatilleke, E., et al. (2000) Increased Intake of Calcium Reverses Vitamin B12 Malabsorption Induced by Metformin. Diabetes Care, 23, 1227-1231. &lt;br&gt;https://doi.org/10.2337/diacare.23.9.1227</mixed-citation></ref><ref id="hanspub.31261-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Bell, D.S. (2010) Metformin-Induced Vitamin B12 Deficiency Presenting as Aperipheral Neuropathy. The Southern Medical Journal, 103, 265-267. &lt;br&gt;https://doi.org/10.1097/SMJ.0b013e3181ce0e4d</mixed-citation></ref></ref-list></back></article>